USA flag logo/image

An Official Website of the United States Government

THE GOAL OF THIS RESEARCH IS THE DEVELOPMENT OF RECOMBINANT CONTRACEPTIVE…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
4837
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4837
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
California Biotechnology, Inc.
2450 Bayshore Parkway Mountain View, CA 94043
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE GOAL OF THIS RESEARCH IS THE DEVELOPMENT OF RECOMBINANT CONTRACEPTIVE VACCINES, USING HUMAN CHORIONIC GONADOTROPIN (HCG) CARBOXY-TERMINAL PEPTIDE (CTP) AS A MODEL SYSTEM.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE GOAL OF THIS RESEARCH IS THE DEVELOPMENT OF RECOMBINANT CONTRACEPTIVE VACCINES, USING HUMAN CHORIONIC GONADOTROPIN (HCG) CARBOXY-TERMINAL PEPTIDE (CTP) AS A MODEL SYSTEM. TO OVERCOME CURRENT CONJUGATION PROBLEMS, GENES ENCODING CON- JUGATED HCG CTP FUSED POLY-PROTEINS CAN BE SYNTHESIZED. TO OVERCOME CURRENT ADJUVANT PROBLEMS, THESE PROTEINS WILL BE DELIVERED AS A RECOMBINANT VACCINIA VACCINE. SPECIFIC AIMS OF THIS PHASE I WORK ARE: (1) CONSTRUCTING MULTIMERIC HCG CTP GENES; (2) CONSTRUCTING VECTORS THAT CREATE INTRA- CELLULAR, SECRETED, AND MEMBRANE-BOUND FORMS OF HCG CTP CONJUGATED POLYPROTEINS; (3) DETERMINING THAT THE POLY- PROTEINS ARE ANTIGENIC; AND (4) RECOMBINING THE GENES INTO VACCINIA VIRUS. PHASE II WILL INVOLVE: (1) CONSTRUCTING FURTHER RECOMBINANT VACCINIA; (2) CLONING CDNA COPIES OF THEBABOON CG (BCG) GENE TO ALLOW PROPER PRIMATE STUDIES OF VACCINE EFFICACY AND SAFETY; (3) TESTING THE ABILITY OF EACHHCG- AND BCG-VACCINIA VACCINE TO RAISE ANTISERA IN RABBITS THAT NEUTRALIZE HCG ACTIVITY IN IN VITRO AND IN VIVO RAT BIOASSAYS; AND (4) INITIATING BABOON STUDIES OF NEUTRALIZINGBCG-AND HCG-VACCINIA CONTRACEPTIVE VACCINES. THE POLY- PROTEIN TECHNOLOGY DEVELOPED WILL BE APPLICABLE TO ANY SUBUNIT OR VACCINIA VACCINE, AND THIS WORK CAN SERVE AS A MODEL FOR VACCINIA VACCINES AGAINST ANY AUTOANTIGEN.

Principal Investigator:

Dr karen d talmadge
PRINCIPAL INVESTIGATOR
4159661550

Business Contact:

Small Business Information at Submission:

California Biotechnology Inc
2450 Bayshore Frontage Road Mountain View, CA 94043

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No